Who owns Spyre Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SYRE from SEC Form 13F filings across 287 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 287 institutions disclosed 101.1M shares of Spyre Therapeutics, Inc. worth $9.00B — about 119.3% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
287
13F holders
$9.00B
value, 2026 filers
119.3%
of shares outstanding (101.1M sh)
67
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of SYRE's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 13.5M | $1.20B | 0.1% | 15.9% | +3.6% |
| 2 | BlackRock, Inc. | 6.8M | $603.6M | 0.0% | 8% | +4.2% |
| 3 | Paradigm Biocapital Advisors LP | 4.5M | $396.8M | 7.9% | 5.3% | +16.1% |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.1M | $361.8M | 0.0% | 4.8% | +74.4% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3.8M | $333.9M | 0.0% | 4.4% | +8.8% |
| 6 | RTW INVESTMENTS, LP | 3.7M | $328.7M | 3.3% | 4.4% | -13.2% |
| 7 | STATE STREET CORP | 3.5M | $314.6M | 0.0% | 4.2% | +15.6% |
| 8 | PERCEPTIVE ADVISORS LLC | 3.3M | $292.1M | 5.1% | 3.9% | -24.0% |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.0M | $270.4M | 0.0% | 3.6% | +2.6% |
| 10 | Janus Henderson Group Ltd.NEW | 2.9M | $257.8M | 0.1% | 3.4% | new |
| 11 | Driehaus Capital Management LLC | 2.8M | $245.8M | 1.7% | 3.3% | -1.4% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $236.4M | 0.0% | 3% | -0.4% |
| 13 | Venrock Adviser, LLC | 2.5M | $221.3M | 10.8% | 2.9% | -16.7% |
| 14 | Capital World Investors | 2.4M | $210.5M | 0.0% | 2.8% | +2.1% |
| 15 | TCG Crossover Management, LLC | 1.9M | $169.2M | 4.8% | 2.2% | 0.0% |
| 16 | TANG CAPITAL MANAGEMENT LLC | 1.9M | $168.5M | 7.7% | 2.2% | 0.0% |
| 17 | BANK OF AMERICA CORP /DE/ | 1.8M | $162.9M | 0.0% | 2.2% | +2.9% |
| 18 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.8M | $157.4M | 0.2% | 2.1% | +2.7% |
| 19 | JPMORGAN CHASE & CO | 1.7M | $146.8M | 0.0% | 2% | +58.1% |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 1.5M | $133.9M | 0.0% | 1.8% | -4.9% |
| 21 | FRANKLIN TEMPLETON INC | 1.4M | $142.2M | 0.0% | 1.7% | -2.5% |
| 22 | Affinity Asset Advisors, LLC | 1.3M | $113.9M | 4.6% | 1.5% | 0.0% |
| 23 | GOLDMAN SACHS GROUP INC | 1.2M | $107.3M | 0.0% | 1.4% | -18.5% |
| 24 | Remedium Capital Partners, LLC | 1.2M | $103.3M | 37.8% | 1.4% | -20.7% |
| 25 | Holocene Advisors, LP | 1.1M | $101.5M | 0.2% | 1.3% | +12.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.